Background
Prematurity is the leading cause of neonatal morbidity and mortality amongst non-anomalous neonates in the United States. Intramuscular 17-alpha hydroxyprogesterone caproate (17OHP-C) injections reduce the risk of recurrent prematurity by approximately one third. Unfortunately, prophylactic 17OHP-C is not always effective, and one-third of high-risk women will have a recurrent PTB despite 17OHP-C therapy. The reasons for this variability in response are unknown. Previous investigators have examined the influence of a variety of factors on 17OHP-C response, but have analyzed data used a fixed outcome of ‘term’ delivery to define progesterone response.
Objective
We hypothesized that the demographics, history, and pregnancy course among women who deliver at a similar gestational age with 17-alpha hydroxyprogesterone caproate (17OHP-C) for recurrent spontaneous preterm birth (SPTB) prevention differs when compared to those women who deliver later with 17OHP-C, and that these associations could be refined by using a contemporary definition of 17OHP-C ‘responder.’
Study Design
This was a planned secondary analysis of a prospective, multi-center, longitudinal study of women with ≥ 1 prior documented singleton SPTB <37 weeks gestation. Data were collected at 3 pre-specified gestational age epochs during pregnancy. All women included in this analysis received 17OHP-C during the studied pregnancy. We classified women as a 17OHP-C responder or non-responder by calculating the difference in delivery gestational age between the 17OHP-C treated pregnancy and her earliest SPTB. Responders were defined as those with pregnancy extending ≥3 weeks later with 17OHP-C compared to the delivery gestational age of their earliest prior SPTB. Data were analyzed using chi-square, t-test, and logistic regression.
Results
155 women met inclusion criteria. The 118 responders delivered later on average (37.7 weeks) than the 37 non-responders (33.5 weeks), p<0.001. Among responders, 32% (38/118) had a recurrent SPTB. Demographics (age, race/ethnicity, education, and parity) were similar between groups. In the regression model, the gestational age of the prior SPTB (OR 0.68, 95% CI 0.56–0.82, p<0.001), vaginal bleeding/abruption in the current pregnancy (OR 0.24, 95% CI 0.06–0.88, p=0.031), and first-degree family history of SPTB (OR 0.37, 95% CI 0.15–0.88, p=0.024) were associated with response to 17OHP-C. Because women with a penultimate preterm pregnancy were more likely to be 17OHP-C non-responders, we performed an additional limited analysis examining only the 130 women whose penultimate pregnancy was preterm. In regression models, the results were similar to those in the main cohort.
Conclusions
Several historical and current pregnancy characteristics define women at risk for recurrent PTB at a similar gestational age despite 17OHP-C therapy. These data should be prospectively studied in larger cohorts and combined with genetic and environmental data to identify women most likely to benefit from this intervention.